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At the conclusion of this session, the participant  
will be able to: 
 
 Describe the current measles situation in the 
United States 
 Discuss the clinical presentation of measles 
and the clinical guidelines for patient 
assessment and management 
 Identify CDC vaccination recommendations 
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Measles and Transmission 
 Febrile rash illness caused by measles virus 
 
 Transmitted via respiratory droplets and aerosol 
 spread by coughing and sneezing, close personal contact or 
direct contact with infected nasal or throat secretions 
 
 Contagious from 4 days before to 4 days after rash 
onset 
 
 R0 = 12-16 with secondary attack rates in susceptible 
household contacts ~ 90% 
 
Measles 
 Prodrome (2-4 days) 
 Fever (up to 105oF) 
 Cough, Coryza, and/or Conjunctivitis  
(the three “C’s) 
 Enanthem (Koplik spots) 
 
 Rash ~14 days after exposure (range 7-21 
days) 
 Maculopapular 
 Spreads from head to trunk to extremities 
 May become confluent 
 Lasts 5-6 days and fades in order of appearance  
Measles Complications  
Complication Counts 
Diarrhea 8% 
Otitis media 7-9% 
Pneumonia 1-6% 
Encephalitis 1 per 1,000 cases 
Death 1 -3 per 1,000 cases 
Subacute Sclerosing 
Panencephalitis (SSPE) 
1 per 100,000 cases 7-10 
years after measles  
More common in children < 5 years and adults 
Measles Annual Disease Burden U.S. 
Decade Prior to Vaccine (1950s) 
 3-4 million estimated and ~ 500,000 reported cases 
 
 48,000 hospitalizations 
 
 4,000 encephalitis cases 
 
 450-500 deaths 
 
Global Burden of Measles 
 Deaths 
 Estimated 2.6 million deaths/year in 1980 
 75% decrease in estimated deaths from 2000 to 2013 
145,700 deaths in 2013 (~400 deaths/day)  
 Remains a leading cause of vaccine preventable deaths in 
children < 5 years old 
 
 Complications with sequelae include blindness 
 
 Cases 
 Estimated 20 million per year 
 72% decrease in reported measles incidence from 2000 to 2013 
 

Measles Outbreak, France, 2008-2011 
(n>20,000, 10 deaths) 
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Measles Elimination* in the U.S. 
• Declared in 2000 and achieved due to: 
– High two-dose vaccine coverage 
– High quality measles surveillance and response 
– Improved measles control in the World Health 
Organization Region of the Americas 
 
• Elimination does not mean “gone forever”  - 












* Defined as interruption of continuous measles transmission for lasting > 12 months 
Measles Cases and Incidence  by Age and 
Vaccination Status, U.S. 2001-2008 
Parker Fiebelkorn et al, JID,  2010;202:1520-1528 
11/24 
20/58 
Unvaccinated and  
traveled abroad 
Measles, United States,  1996-2014* 
(Importations indicated by red bar, available since 2001) 



















Infographic on travel and cases 
Measles Epidemiology US, 2001-2011 
 Median 60 cases/year (range 37 to 220) 
 Importations ~ 33/year, majority in US residents 
 ~ 25 % cases hospitalized 
 2 deaths in approximately 1,000 cases 
 Incidence < 1 case/million population 
 Highest age-specific incidence in infants, lowest in adults 
 Vaccination status 
 65% unvaccinated 
 20% unknown vaccination status 
 15% vaccinated 
 4 outbreaks/year (range 2-12) 
 Median size 6 cases (3-34 cases) 
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Measles 2011 - 2014 
 Reported cases  220, 55, 189, 644 
 Median 205 
 Mean 277 
 Importations and Outbreaks  
 2011 80 importations  14 outbreaks  3 – 21 cases 
 2012 21 importations  4 outbreaks  3 - 14 cases 
 2013 54 importations   11 outbreaks  3 - 58 cases 
 2014 60 importations  23 outbreaks 3 – 383 cases 
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Distribution of measles genotypes 
from Dec-2013 to Nov-2014 (12M period) 
Data source: MeaNS Database; 20 January 2015 
Updated on 20 January 2015 
The boundaries and names shown and the designations used on this map do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization 
concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries.  Dotted lines on maps represent 
approximate border lines for which there may not yet be full agreement. ©WHO 2014. All 
rights reserved. 
Countries with Genotype data available 
Measles, U.S., 1997-2014* 
































*Provisional total 2014 
 
Measles, U.S., 1997-2015* 

































* Provisional total 2014 
* 2015 data through Jan 30 
Jan 2015 
Measles U.S. 2014* 
 644 cases reported from 27 states including 23 
outbreaks 
 60 importations  
25 from the Philippines and 9 from India 
54 (91%) among US residents 
 98% cases import-associated 
 78 cases (12%) hospitalized 
 
 Cases in US residents (N=635) 
 77% unvaccinated 
 15% unknown vaccination status (most are adults) 
  8% vaccinated  
 Among unvaccinated 
  79% were personal belief exemptors  
   3% travelers age 6 months to 4 years  
   8% were  too young to be vaccinated 
  10% unknown/misc  




cases Countries of travel 




European 6 Dubai/Germany/London (1), Republic of Georgia 
(1), Netherlands (1), France/Belgium (1), Greece 
(1), 
Barcelona/Paris (1) 
Americas 3 Brazil (1), Canada (1), Chile (1) 
South-East Asia 15 India  (9), Indonesia (4), Sri Lanka (1), Thailand/S 
Korea (1) 
Western Pacific 34 China (4), Philippines (25), Singapore (1), Saipan 
(1),  
Vietnam (1), SE Asia/Philippines (1), FSM (1)  
  *provisional   data  
Measles, United States, 2014  




Measles 2015: Other highlights 
 Most cases unvaccinated or with 
unknown vaccination status 
 6 importations from Azerbaijan, 
Indonesia, Qatar, Pakistan, 
Dubai/India, Singapore/Indonesia  
 Adult and child cases  
 Measles genotypes B3 , D8 and D9 
 Child care center cases IL 
• 9 confirmed measles cases in babies < 
12 months and one case in an adult 
• Investigation ongoing – source? 
Measles Outbreaks (>20 cases) 







Iport Status Genotype Setting 
1st & last rash 
onsets 
Duration Median Age 
Age 
Range 







23 y (early) 
13 y (late) 
2 wks – 53 y 
2014/15 Disneyland CA + 6 125 Imported-virus B3 Community 12/28/2014 - Ongoing 19 y 6 mos – 70 y 






10 y (early) 
19 mos (late) 
0 mos – 32 y 
2014 KC Metro 
MO/KS 
(TX/NE) 
43 Imported-virus B3 Community 
5/5/2014 –  
7/18/2014 






















7 weeks 10 y 8 mos - 43 y 
2014 Manhattan NYC 25 Imported-virus B3 Community 
2/11/2014 – 
3/24/2014 




NC 23 Imported (India) D8 Community 
4/5/2013 – 
5/7/2013 


















2/15/2011 -  
4/24/2011 










10 weeks 15 m 5 mos – 11y 
*as of February 13, 2015 
Measles outbreak response has a high  
economic burden in the U.S. 
*Public health and health care costs  expended to control the spread of measles 





Estimated public health cost* 
2011 US 107 (16) $2.7-5.3M 
2011 Utah 13 (2) >$330,000 
2008 California 12 (1) $125,000 
2008 Arizona 14 (1) $800,000 
(limited to cost for 2 hospitals to respond to 7 
cases in their facilities) 
2005 Indiana 34 (1) $168,000 
2004 Iowa 1  $142,000 
Measles and MMR Vaccines 
 Live, viral vaccines 
 Measles vaccine licensed in 1963 
 Combination MMR vaccine licensed in 1971 
Only MMR vaccine is available now in the US 
 
 Excellent safety profile with 50+ years use 
 Low risk of febrile seizures in children 12-23 months (1 in 3,000 doses) 
 Temporary pain/stiffness in joints, mostly in teenage or adult women 
 Temporary low platelet count – ITP (~ 1 out of 30,000 doses) 
 
 Vaccine Effectiveness 
 1-dose: ~93% 
 2-dose: ~97% 
 
MMR Vaccine Routine Recommendations* 
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf 
*ACIP, AAP/COID, AAFP,  ACOG, ACP, ACNM available at  http://www.cdc.gov/vaccines/schedules/hcp/adult.html 
 Children and adolescents 
 Two doses at 12-15 months and 4-6 years or at least 28 days 
after the first dose 
 Catch up vaccination as needed 
 
 Adults without evidence of measles immunity 
 Two doses (healthcare personnel, post high school students, 
travelers) 
 One dose (others) 
MMR Vaccine Travel Recommendations 
 Persons aged ≥12 months without other evidence of 
immunity should receive 2 doses* 
 Includes providing a 2nd dose to children prior to age 4-6 yrs 
 Includes adults** who have only received one routine dose in the past 
 
 Children aged 6-11 months should receive 1 dose 
 If vaccinated at age 6-11 months, still need 2 subsequent doses at 
age ≥12 months  
* 2nd dose of MMR vaccine should be administered at least 28 days after the 1st dose 
** Born in 1957 or later 
MMR Vaccination Coverage  
 National Immunization Survey, U.S., 1995-2013 
NIS data available at http://www.cdc.gov/vaccines/imz-managers/coverage/imz-coverage.html 













MMR 1+ (19-35 mo) MMR 2+ (13-17 yr)
Mean (95% CI) Rates of Nonmedical Exemptions  
by Type & Ease of Exemption, 2006–2011, US 
Omer  et al., NEJM, 2012  
The Eas 
Suspected Measles: Diagnosis and Response 
 Many U.S healthcare professionals have never seen a 
case of measles 
 
 Delay in diagnosis contributes to transmission 
 
 Consider measles in differential diagnosis of febrile 
rash illness 
 e.g. Kawasaki’s, Scarlet fever, Dengue 
 Travel History or Exposure to Recent Travelers or measles in the 
local community  
 Especially in an unvaccinated person 
 
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html 
  
Suspected Measles: Diagnosis, Response  
and Treatment 
 Lab testing 
 Serology for IgM  
 Viral specimen (nasopharyngeal, oropharyngeal, or nasal swab) 
for PCR (and genotyping) 
 Acute and convalescent specimens for IgG may be useful, 
especially in vaccinated cases  
 
 Report immediately to local health department 
 
 Offer vaccine or immune globulin immediately to 
household members without evidence of immunity 
 
 
CDC guidance available at CDC Measles Vaccine Guidance 
 
Suspected Measles: Diagnosis, Response  
and Treatment 
 Treat children with severe measles (e.g. hospitalized) 
with vitamin A 
 Administer vitamin A immediately on diagnosis and repeat 
the next day.  The recommended age-specific daily doses are 
50 000 IU for infants aged <6 months 
100 000 IU for infants aged 6–11 months 
200 000 IU for children aged ≥12 months 
 
 
WHO WER 2009 Measles vaccines WHO position paper http://www.who.int/wer/2009/wer8435.pdf 
AAP Red Book 2015 (available online) 
 
  
Public Health Response 
(for confirmed and suspect cases) 
 Isolation of cases 
 Infectious period 4 days prior through 4 days after date of rash 
onset 
 
 Notification and Surveillance 
 Immediately notifiable to CDC (within 24 hours) 
 Contact CDC Quarantine Station if relevant travel 
 Alert physicians statewide 
 Enhanced measles surveillance 
 
 Contact investigations and response efforts 
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html 
  
Measles Isolation Guidance 
 If measles is suspected in a clinic, ER or hospital 
setting, isolate immediately 
 
 Airborne isolation room or private room with the 
door closed, mask patient if feasible 
 
 Ensure healthcare personnel have evidence of 
immunity 
 
 In hospital setting, respiratory precautions including 
N95 masks or PAPR, even for those with evidence of 
immunity 
ACIP and CDC guidance available at http://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf 
and http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf 
Contact Investigation for Exposure to Measles 
 Persons exposed during cases infectious period 
 Includes exposure to area 2 hours after case left 
 
 Establish presumptive evidence of immunity for 
contacts 
 
 Quarantine of contacts without presumptive 
evidence of immunity (through 21 days after 
exposure) 
 
 Postexposure prophylaxis (PEP) 
 Vaccine or Immune globulin (IG) 
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html 
  
Presumptive Evidence of Immunity for Measles 
Routine 
Students at post-high 
school educational 
institutions  
Health-care personnel International travelers 
(1) Documentation of 
age-appropriate 





children: 1 dose 
–school-aged children 
(grades K-12): 2 doses  




(2) Laboratory evidence 
of immunity, or 
 
(3) Laboratory 
confirmation of disease, 
or 
 
(4) Born before 1957 
(1) Documentation of 
vaccination with 2 doses 
of live measles virus-
containing vaccine, or 
 
(2) Laboratory evidence 
of immunity, or  
 
(3) Laboratory 
confirmation of disease, 
or 
 
(4) Born before 1957 
(1) Documentation of 
vaccination with 2 doses 
of live measles virus-
containing vaccine, or 
 
(2) Laboratory evidence 
of immunity, or  
 
(3) Laboratory 
confirmation of disease, 
or 
 
(4) Born before 1957 
 
- should consider 2 
doses 
- must provide 2 doses 
during outbreak 
response unless 
serologic evidence of 
immunity  
 
(1) Documentation of 
age-appropriate 




–infants aged 6–11 
months: 1 dose 
–persons aged ≥12 
months: 2 doses, or  
 
(2) Laboratory evidence 
of immunity, or  
 
(3) Laboratory 
confirmation of disease, 
or 
 
(4) Born before 1957 
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf 
Postexposure Prophylaxis (PEP) 
MMR Vaccine 
 Administer within 72 hours of exposure 
 May return to normal activities (except health care settings) 
 Still monitor for symptoms 
 Can be given down to age 6 months 
 Be aware of possibility of vaccine rash 
 
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf 
  
Postexposure Prophylaxis (PEP) 
Immune Globulin 
 Administer within 6 days of exposure 
 
 Recommended Dose 
 Intramuscular (IGIM): 0.5 mL/kg (max = 15 mL) 
 Intravenous (IGIV): 400 mg/kg 
 
 Recommended for the following groups (risk of 
severe disease and complications) 
Infants aged <12 months (IGIM) 
Pregnant women without evidence of immunity (IGIV) 
Severely immunocompromised patients (IGIV) 
 
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html 
 and 2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf 
 
Measles In the Postelimination Era 
 Measles is due to Failure to Vaccinate 
 
 Measles Elimination is a Global Problem 
 Continued threat of importations 
 
 Measles occurs in the U.S. 
 
 Maintenance of Elimination is Resource Intensive 
 Maintaining vaccine coverage 
 Intensive case/contact investigations 
 Healthcare workers diagnostic skills 
 Advanced laboratory techniques 
Up-To-Date Outbreak and Case Information 
45 
http://www.cdc.gov/measles/cases-outbreaks.html 
 Updated weekly 
(on Mondays) 
 










 Clinical Information 
 Complications  
 Transmission 
 Practice Guidelines 
 Diagnosis  
 Lab testing 
 Isolation & Treatment 
 Vaccination Recs 
 Children & Adults 
 International Travelers 
 Measles Images 
 
Resources for Healthcare Professionals 
 Webinar:  Measles 2014 Update-Clinical Presentation, 
Outbreaks, Vaccination Recommendations, & Patient 
Management 
 http://www.vicnetwork.org/ -  
 
 NetConference:  Why Measles Matters 
 http://www.cdc.gov/vaccines/ed/ciinc/2014-05-22.html -  
 
 Medscape video: Five minute measles overview 
 http://www.medscape.com/viewarticle/828508 -   
 
 Children with Measles Video 
 http://www.cdc.gov/vaccines/ed/epivac/default.htm -  (Session 6) 
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Resources for Healthcare Professionals  (cont.) 
 CDC Fact Sheets and Resources 
 Fact sheets on measles and MMR vaccine safety  
    to guide discussions with patients and parents 
 http://www.cdc.gov/vaccines/hcp/patient-
ed/conversations/index.html -  
 
 




 Put CDC’s Measles Content for Clinicians on  
     Your Website 
 Easy steps to syndicate CDC’s measles information 











Resources for the Parents and Caregivers 
 Fact sheets, Measles FAQ, Posters 
 
 NEW Infographic and Videos 
 
 Matte/drop-in articles for childcare  
     providers to use in newsletters and e-mails 
 
 Measles Feature  
 http://www.cdc.gov/features/measles/ 
 
 Put CDC’s Measles Content for the  
     Public on Your Website 
 https://tools.cdc.gov/syndication/pages.aspx?topicId=28032 
 




 State and local health departments 
 




 Greg Wallace 
 Amy Fiebelkorn 
 Paul Gastanaduy 
 Susan Redd 
 Mark Papania 
 Susan Reef 
 William Bellini 
 Nakia Clemmons 
 
 Paul Rota 
 Jennifer Rota 
 Mark Pallansch 
 Ismael Ortega-Sanchez 
 Jeanette St Pierre 
 Sarah Poser 
 Jessica Allen 
 Teresa Smith 





To Ask a Question 
 Using the Webinar System 
 “Click” the Q&A tab at the top left of the webinar tool bar 
 “Click”  in the white space 
 “Type” your question 
 “Click” ask 
 
 On the Phone 
 Press Star (*) 1 to enter in the queue to ask a question 
 State your name 
 Listen for the operator to call your name  
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   Thank you for joining! 
Please email us questions at coca@cdc.gov  
 









When:  A few days after the live call 
 
What:  All call recordings (audio, webinar, and 
transcript) 
 
Where:  On the COCA Call webpage  
http://emergency.cdc.gov/coca/calls/2014/callinfo_021915.asp   
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Join Us on Facebook 
 CDC Facebook page for 
Health Partners! “Like” our 
page today to receive COCA 
updates, guidance, and 
situational awareness about 
preparing for and responding 





 CDC Health Partners Outreach 
(http://www.facebook.com/CDCHealthPartnersOutreach) 
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